Khiron Life Sciences Corp. is opening a new Zerenia clinic location and a new retail pharmacy in Colombia. The clinic is located in the city of Bogota, with a maximum annual capacity of 40,000 consults per year. (Benzinga) In addition, the company has opened its first retail pharmacy location within El Ensueño shopping mall. This pharmacy will allow the company to sell medical cannabis products to patients outside its own Zerenia network and dispense high and low THC medical cannabis to insurance companies in the country. Alvaro Torres, Khiron CEO and director stated, “Khiron has become a clear leader in the Colombian medical cannabis market because of its unique go-to-market strategy, anchored in our Zerenia clinic model. This new expansion within Bogota capitalizes on the Colombian government’s decision on mandatory insurance coverage, and we aim to get closer to our patients and insurers, to improve their quality of life. With our new retail pharmacy, we aim to be able to offer more access to patients outside our clinic network and to provide a dispensing alternative to insurers, thereby increasing our market leadership within Colombia.

420 Intel – Marijuana Industry News, 04/12/2022 20:00:00

Open article: https://420intel.com/articles/2022/04/13/khiron-opens-new-zerenia-clinic-and-medical-cannabis-pharmacy-colombia

FSD Pharma Inc. (formerly, Century Financial Capital Group Inc., the “Corporation”) announced that it has completed its previously announced business combination with FV Pharma Inc. (“FV Pharma”). On March 9, 2018, the Corporation and FV Pharma entered into an arm’s length definitive business combination agreement (the “Business Combination Agreement”) with 2620756 Ontario Inc. (“SubCo”), a wholly-owned subsidiary of the Corporation, incorporated for the purpose of this transaction. Pursuant to the Business Combination Agreement, the Corporation changed its name to FSD Pharma Inc. and completed a business combination with FV Pharma by way of a three-cornered amalgamation pursuant to which FV Pharma amalgamated with SubCo (the “Transaction”). The resulting amalgamated corporation carried on in the name of FV Pharma as a wholly-owned subsidiary of the Corporation. Following the completion of the Transaction, FSD Pharma Inc. will carry on the medical cannabis business of FV Pharma. For the purposes of this press release, the term “Resulting Issuer” means the Corporation following completion of the Transaction.

Hemp Land, Cannabis Hemp Blog, 04/13/2022 05:38:00

Open article: https://hempland.net/fsd-pharma-announces-closing-of-business-combination-and-conditional-approval-from-the-cse/

As trust in the pharmaceutical companies wanes in the U.S., the firms are turning towards ‘patient influencers’ to use trusted figures in online communities to help hawk drugs to patients, experts warn. A team at the University of Colorado, Boulder, warns in a report published last week that pharmaceutical companies are using internet micro-celebrities to help push drugs to consumers. While Direct-to-Consumer (DTC) drug advertisements are heavily regulated, by using these so-called ‘patient influencers’, the companies can avoid some of the standard disclosures required by law to sell prescription drugs. Experts warn that these ‘patient influencers’ are not major celebrities, but instead smaller figures that may have built a more personal connection with their following. Kim Kardashian was the first influencer to take part in DTC marketing for pharma companies when she posted an Instagram ad for an anti-nausea drug in 2015 Researchers find that Americans use online forums and social media sites when making health care decisions because access and time with doctors can be limited Advertising DTC is a rare practice across the world, but something an average American is strongly familiar with.

Mansur Shaheen U.S., Daily Mail, 04/12/2022 17:41:00

Open article: https://www.dailymail.co.uk/health/article-10712717/Experts-warn-patient-influencers-paid-big-pharma-companies-hawk-drugs.html